Merck Vioxx
Executive Summary
FDA's Arthritis Advisory Committee will review Merck's COX-2 inhibitor Vioxx (rofecoxib) on April 20 for treatment of acute or chronic signs and symptoms of osteoarthritis and management of pain. The meeting will begin at 8 a.m. at the Holiday Inn in Gaithersburg, Md. The Vioxx NDA (21-042) was submitted on Nov. 23 and is receiving a six-month priority review at FDA